ES2162863T3 - Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. - Google Patents

Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.

Info

Publication number
ES2162863T3
ES2162863T3 ES94916201T ES94916201T ES2162863T3 ES 2162863 T3 ES2162863 T3 ES 2162863T3 ES 94916201 T ES94916201 T ES 94916201T ES 94916201 T ES94916201 T ES 94916201T ES 2162863 T3 ES2162863 T3 ES 2162863T3
Authority
ES
Spain
Prior art keywords
fragment
antibody
functionalized
camelidae
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94916201T
Other languages
English (en)
Inventor
Raymond Hamers
Cecile Hamers-Casterman
Serge Victor M Muyldermans
Leon Gerardus J Frenken
Cornelis Theodorus Verrips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vrije Universiteit Brussel VUB
Universite Libre de Bruxelles ULB
Unilever NV
Original Assignee
Vrije Universiteit Brussel VUB
Universite Libre de Bruxelles ULB
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27235299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2162863(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vrije Universiteit Brussel VUB, Universite Libre de Bruxelles ULB, Unilever NV filed Critical Vrije Universiteit Brussel VUB
Application granted granted Critical
Publication of ES2162863T3 publication Critical patent/ES2162863T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE PROPORCIONA UNA PROCESO PARA LA PRODUCCION DE UN ANTICUERPO O UN FRAGMENTO O FRAGMENTO (FUNCIONALIZADO) DEL MISMO UTILIZANDO UN HUESPED EUCARIOTICO BAJO TRANSFORMADO QUE CONTIENE UNA SECUENCIA DE ADN EXPRESABLE QUE CODIFICA EL ANTICUERPO O EL FRAGMENTO (FUNCIONALIZADO) DEL MISMO, DONDE EL ANTICUERPO O FRAGMENTO (FUNCIONALIZADO DEL MISMO) SE DERIVA DE UNA CADENA PESADA DE INMUNOGLOBULINA DE CAMELIDAE Y ESTA DESPROVISTO DE CADENAS LIGERAS, DONDE EL HUESPED EUCARIOTICO BAJO ES UN HONGO, QUE PERTENECE PREFERENTEMENTE AL GENERO ASPERGILLUS O TRICHODERMA, O UNA LEVADURA, QUE PERTENECE PREFERENTEMENTE AL GENERO DE LAS LEVADURAS SACCHAROMUYCES, KLUYVEROMYCES, HANSENULA, O PICHIA. EL FRAGMENTO DE CADENA PESADA PUEDE CONTENER AL MENOS EL DOMINIO VARIABLE COMPLETO. UNA REGION DETERMINANTE COMPLEMENTARIA (CDR) DIFERENTE DE LA CDR QUE PERTENECE AL ANTICUERPO NATURAL EX CAMILIDAE PUEDE INJERTARSE EN EL SOPORTE DEL DOMINIO VARIABLE DE LA CADENA PESADA DE INMUNOGLOBINA. LOS ANTICUERPOS CATALIZADORES PUEDEN SER CULTIVADOS EN LA CAMELIDAE FRENTE A LAS MOLECULAS DE ESTADO DE TRANSICION. EL ANTICUERPO FUNCIONALIZADO O FRAGMENTO DEL MISMO PUEDE CONTENER UNA PROTEINA DE FUSION TANTO DE UNA CADENA PESADA DE CAMELIDAE O UN FRAGMENTO DE LA MISMA Y OTRO POLIPEPTIDO, POR EJEMPLO UNA ENZIMA, PREFERENTEMENTE UNA OXIDO-REDUCTASA. TAMBIEN SE PROPORCIONAN NUEVOS PRODUCTOS QUE SE PUEDEN OBTENER MEDIANTE UN PROCESO COMO EL DESCRITO, Y COMPOSICIONES QUE CONTIENEN UN PRODUCTO PRODUCIDO POR UN PROCESO COMO EL DESCRITO, CUYA COMPOSICION PUEDE CONTENER UN NUEVO PRODUCTO COMO EL DESCRITO.
ES94916201T 1993-04-29 1994-04-28 Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. Expired - Lifetime ES2162863T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP93201239 1993-04-29
EP93201454 1993-05-19
EP93202079 1993-07-15

Publications (1)

Publication Number Publication Date
ES2162863T3 true ES2162863T3 (es) 2002-01-16

Family

ID=27235299

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94916201T Expired - Lifetime ES2162863T3 (es) 1993-04-29 1994-04-28 Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.

Country Status (7)

Country Link
US (2) US6838254B1 (es)
AT (1) ATE204325T1 (es)
AU (1) AU6796094A (es)
DE (1) DE69427974T2 (es)
DK (1) DK0698097T3 (es)
ES (1) ES2162863T3 (es)
WO (1) WO1994025591A1 (es)

Families Citing this family (720)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0739981A1 (en) * 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US20040248201A1 (en) * 1996-06-27 2004-12-09 Serge Muyldermans Recognition molecules interacting specifically with the active site or cleft of a target molecule
GB9620093D0 (en) * 1996-09-26 1996-11-13 Unilever Plc Photofading inhibitor derivatives and their use in fabric treatment compositions
AU8437398A (en) 1997-06-13 1998-12-30 Unilever Plc Bleaching enzymes
WO1999023221A2 (en) * 1997-10-27 1999-05-14 Unilever Plc Multivalent antigen-binding proteins
ATE535154T1 (de) 1998-03-12 2011-12-15 Vhsquared Ltd Produkten die inaktivierte hefen oder schimmel enthalten, die auf ihrer aussenoberfläche aktive antikörper haben
EP0954978B1 (en) 1998-03-12 2011-11-30 VHsquared Limited New products comprising inactivated yeasts or moulds provided with active antibodies
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
TR200101638T2 (tr) * 1998-12-11 2001-10-22 Unilever N.V. Ağartıcı enzimler ve bu enzimleri içeren deterjan bileşimleri
AU2291700A (en) * 1999-01-19 2000-08-07 Unilever Plc Method for producing antibody fragments
CN1252264C (zh) 1999-04-22 2006-04-19 荷兰联合利华有限公司 利用单价抗原-结合蛋白抑制病毒感染
WO2001007555A1 (en) 1999-07-27 2001-02-01 Unilever N.V. Bleaching detergent compositions
EP1118669A3 (en) * 1999-12-17 2001-08-29 Unilever Plc Production of camelid antibodies in plants
WO2001046356A2 (en) 1999-12-22 2001-06-28 Unilever N.V. Method of treating fabrics
EP1242572A2 (en) 1999-12-22 2002-09-25 Unilever N.V. Method of delivering a benefit agent
CA2395138A1 (en) 1999-12-22 2001-06-28 Unilever Plc Method of treating fabrics and apparatus used therein
ATE377068T1 (de) 1999-12-22 2007-11-15 Unilever Nv Tensidzusammensetzungen, verbesserungsmittel enthaltend
ATE273323T1 (de) 1999-12-28 2004-08-15 Esbatech Ag INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN
EP1134231B1 (en) * 2000-03-14 2009-04-15 Unilever N.V. Antibody heavy chain variable domains against human dietary lipases, and their uses
CA2429544C (en) 2000-11-17 2010-10-19 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
ATE513854T1 (de) * 2000-12-13 2011-07-15 Bac Ip B V Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
AU2002235761A1 (en) 2000-12-19 2002-07-01 Unilever Plc Stabilization of antibodies or fragments thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2457636C (en) 2001-08-10 2012-01-03 Aberdeen University Antigen binding domains
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1318195A1 (en) * 2001-12-10 2003-06-11 CatchMabs B.V. A structure for presenting desired peptide sequences
EP1474444A1 (en) 2002-01-10 2004-11-10 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. A novel splice variant of myd88 and uses thereof
ES2496493T3 (es) 2002-01-11 2014-09-19 Bioasis Technologies Inc. Uso de p97 como sistema de administración de enzimas para la administración de enzimas lisosómicas terapéuticas
EP1495055B1 (en) * 2002-04-18 2013-08-14 Genencor International, Inc. Production of functional antibodies in filamentous fungi
US7572442B2 (en) 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Selected antibody compositions for binding to aminophospholipids
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
EP2314629B2 (en) 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
AU2003251238A1 (en) 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
WO2004016750A2 (en) 2002-08-14 2004-02-26 Macrogenics, Inc. FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
JP4731907B2 (ja) * 2002-09-16 2011-07-27 アドバンスド バイオニュートリション コーポレーション 受動免疫のための蛋白質およびペプチド発現
EP2284192A3 (en) * 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US6974860B2 (en) * 2002-12-30 2005-12-13 Kimberly-Clark Worldwide, Inc. Target recognizing binding agents
AU2004208860A1 (en) * 2003-02-06 2004-08-19 Novozymes A/S Human heavy chain antibody expression in filamentous fungi
KR20110094361A (ko) 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 il­9 항체 및 그의 용도
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
EP1668111A4 (en) 2003-08-08 2008-07-02 Genenews Inc OSTEOARTHRITIS BIOMARKERS AND USES THEREOF
JP4943161B2 (ja) 2003-12-23 2012-05-30 ジェネンテック, インコーポレイテッド 新規抗il13モノクローナル抗体での癌の処置
AU2005205412B2 (en) 2004-01-20 2011-08-11 Merus N.V. Mixtures of binding proteins
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
DK2330121T3 (en) 2004-06-02 2014-12-15 Adalta Pty Ltd Binding moieties based on shark IgNar domains
CN1942203A (zh) * 2004-06-04 2007-04-04 金克克国际有限公司 使用抗体重链的筛选方法
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
FR2879605B1 (fr) * 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
CA2593328C (en) 2005-01-14 2018-02-06 Ablynx N.V. Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between von willebrand factor (vwf) and platelets
CN103497993A (zh) 2005-02-07 2014-01-08 基因信息公司 轻度骨关节炎生物标志物及其用途
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
MX2007014564A (es) 2005-05-20 2008-02-07 Ablynx Nv Anticuerpos de vhh de dominio unico contra el factor de von willebrand.
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
EP2295080A3 (en) 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
US9017662B2 (en) 2005-08-30 2015-04-28 Actogenix N.V. Anti-TNF alpha producing lactic acid bacteria for the treatment of chronic enterocolitis
LT1931710T (lt) 2005-08-31 2017-03-27 Merck Sharp & Dohme Corp. Rekombinantiniai anti-il-23 antikūnai
SI1933869T1 (sl) 2005-09-01 2010-02-26 Schering Corp Uporaba IL-23 in IL-17 antagonistov za zdravljenje avtoimunske očesne vnetne bolezni
JP5237817B2 (ja) 2005-10-21 2013-07-17 ジーンニュース インコーポレーティッド バイオマーカー産物レベルを疾患に相関させるための方法および装置
PT2500030E (pt) 2005-11-04 2015-09-24 Genentech Inc Uso de inibidores da via do complemento para tratar doenças oculares
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-22(il-22)之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
EP1999147A1 (en) * 2006-03-27 2008-12-10 Ablynx N.V. Medical delivery device for therapeutic proteins based on single domain antibodies
CA2651567A1 (en) * 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
MX2008015771A (es) 2006-06-14 2009-01-27 Macrogenics Inc Metodos para el tratamiento de padecimientos autoinmunes usando anticuerpos monoclonales con toxicidad reducida.
US8874380B2 (en) 2010-12-09 2014-10-28 Rutgers, The State University Of New Jersey Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
AU2007281876B2 (en) 2006-06-26 2013-09-05 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
EA021255B1 (ru) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Антагонистические моноклональные антитела человека, специфичные в отношении light человека
KR20090088852A (ko) 2006-09-05 2009-08-20 메다렉스, 인코포레이티드 골형성 단백질의 항체와 이의 수용체 및 이의 사용방법
ES2625798T3 (es) 2006-10-02 2017-07-20 E. R. Squibb & Sons, L.L.C. Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
SI3028716T1 (sl) 2006-10-10 2021-01-29 Regenesance B.V. Komplementarna inhibicija za izboljšano regeneracijo živcev
US8173423B2 (en) 2006-11-07 2012-05-08 Vib Vzw Diagnosis and treatment of T-cell acute lymphoblastic leukemia
EP2097097B1 (en) 2006-12-01 2018-05-30 E. R. Squibb & Sons, L.L.C. Antibodies, in particular human antibodies, that bind cd22 and uses thereof
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
AU2007333098A1 (en) 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind CD70 and uses thereof
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
RU2493167C2 (ru) 2006-12-18 2013-09-20 Дженентек, Инк. АНТИТЕЛА-АНТАГОНИСТЫ ПРОТИВ Notch3 И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С Notch3 ЗАБОЛЕВАНИЙ
AU2007336243B2 (en) 2006-12-19 2012-07-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
CA2673331A1 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
SG178804A1 (en) 2007-02-23 2012-03-29 Schering Corp Engineered anti-il-23p19 antibodies
DK2426144T3 (en) 2007-02-23 2019-01-07 Merck Sharp & Dohme Manipulated Anti-IL-23P19 Antibodies
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EP2447719B1 (en) 2007-02-26 2016-08-24 Oxford BioTherapeutics Ltd Proteins
CA2679400A1 (en) 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
NZ579251A (en) 2007-02-28 2012-06-29 Schering Corp Engineered anti-il-23r antibodies
CN103275216B (zh) 2007-03-12 2015-05-06 艾斯巴技术-诺华有限责任公司 单链抗体的基于序列的工程改造和最优化
SI2308514T1 (sl) 2007-03-23 2013-09-30 To-Bbb Holding B.V. Konjugati za prenos zdravila preko krvno-moĹľganske pregrade
WO2008134046A1 (en) 2007-04-27 2008-11-06 Genentech, Inc. Potent, stable and non-immunosuppressive anti-cd4 antibodies
EP2164868B1 (en) 2007-05-04 2015-03-25 Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA Engineered rabbit antibody variable domains and uses thereof
DK3072525T3 (en) 2007-05-14 2018-04-30 Astrazeneca Ab PROCEDURES FOR REDUCING BASOFILE CELL LEVELS
AU2008262384B9 (en) 2007-06-05 2014-11-27 Yale University Inhibitors of receptor tyrosine kinases and methods of use thereof
KR101530723B1 (ko) * 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
DK2158315T3 (en) * 2007-06-25 2016-06-06 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies and modified antibodies with improved functional properties
AU2008270274B2 (en) 2007-07-03 2012-06-28 Ablynx N.V. Providing improved immunoglobulin sequences by mutating CDR and/or FR positions
US8501907B2 (en) * 2007-08-10 2013-08-06 Janssen Biotech, Inc. Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
CA2696011A1 (en) * 2007-08-10 2009-02-19 Centocor Ortho Biotech Inc. Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
PE20090993A1 (es) 2007-08-29 2009-07-08 Sanofi Aventis Anticuerpos anti-cxcr5 humanizados y derivados de los mismos
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US8216571B2 (en) 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
WO2009068631A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
KR101577843B1 (ko) 2007-12-14 2015-12-16 브리스톨-마이어스 스큅 컴퍼니 인간 ox40 수용체에 대한 결합 분자
JP5889533B2 (ja) 2008-01-31 2016-03-22 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 改変された抗体定常ドメイン分子
CA2717015A1 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
AU2009235467A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Single variable domains against the Notch pathways
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽,以及包含其的化合物、构建体和多肽
WO2010011944A2 (en) 2008-07-25 2010-01-28 Wagner Richard W Protein screeing methods
KR101442323B1 (ko) 2008-09-07 2014-09-25 글라이코넥스 인코포레이티드 항-연장된 ⅰ형 글라이코스핑고지질 항체, 이의 유도체 및 용도
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
MX2011006549A (es) 2008-12-19 2011-07-20 Schering Corp Suplemento alimenticio para el cultivo de celula de mamifero y metodos de uso.
CA2750581A1 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
US20100260752A1 (en) 2009-01-23 2010-10-14 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
US20100189919A1 (en) * 2009-01-27 2010-07-29 Xerox Corporation Imaging System And Process Using Monoclonal Antibodies
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
PT2403878T (pt) 2009-03-05 2017-09-01 Squibb & Sons Llc Anticorpos completamente humanos específicos a cadm1
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
CA2753388C (en) 2009-03-23 2016-11-29 Quark Pharmaceuticals, Inc. Endo180 antibody to treat cancer and fibrotic disease
EP3009454A3 (en) 2009-04-20 2016-10-19 Oxford Bio Therapeutics Limited Antibodies specific to cadherin-17
SG175305A1 (en) 2009-04-23 2011-11-28 Theraclone Sciences Inc Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
HUE053480T2 (hu) 2009-04-30 2021-06-28 Ablynx Nv Eljárás domén ellenanyagok elõállítására
US20120128673A1 (en) 2009-05-20 2012-05-24 Schering Corporation Modulation of pilr receptors to treat microbial infections
US9150640B2 (en) 2009-07-10 2015-10-06 Ablynx N.V. Method for the production of variable domains
IN2012DN00863A (es) 2009-07-31 2015-07-10 Medarex Inc
LT2805731T (lt) 2009-09-03 2019-02-11 Ablynx N.V. Stabilios polipeptidų kompozicijos ir jų panaudojimas
PT3023438T (pt) 2009-09-03 2020-05-08 Merck Sharp & Dohme Anticorpos anti-gitr
EP2470569A1 (en) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antibodies against epha10
EP2489724A4 (en) * 2009-10-16 2013-05-01 Kaneka Corp HANSENULA POLYMORPHA SUITABLE FOR ANTIBODY PRODUCTION, ANTIBODY MANUFACTURING METHODS THEREFOR AND ANTIBODIES MANUFACTURED IN THIS PROCEDURE
US20120282177A1 (en) 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
CA2779384C (en) 2009-11-04 2018-02-27 Schering Corporation Engineered anti-tslp antibody
US20120282276A1 (en) 2009-11-05 2012-11-08 The Regents Of The University Of Michigan Biomarkers predictive of progression of fibrosis
DK2509409T3 (en) * 2009-12-10 2016-11-14 Regeneron Pharma MICE, WHICH PRODUCES HEAVY CHAIN ANTIBODIES
WO2011084357A1 (en) 2009-12-17 2011-07-14 Schering Corporation Modulation of pilr to treat immune disorders
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
CN102781959A (zh) 2010-02-05 2012-11-14 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽
ES2738114T3 (es) 2010-02-11 2020-01-20 Ablynx Nv Métodos y composiciones para la preparación de aerosoles
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
CA2798432A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
EA201291181A1 (ru) 2010-05-06 2013-05-30 Новартис Аг Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
CN102242094A (zh) * 2010-05-14 2011-11-16 浙江大学 一种提高alpha半乳糖苷酶活力持续性的方法
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
AU2011273360A1 (en) 2010-07-02 2013-02-07 Vib Vzw The role of Fragile X mental retardation gene and protein in cancer metastasis
GB201012845D0 (en) 2010-07-30 2010-09-15 Vib Vzw Inhibition of dicer function for treatment of cancer
SG187908A1 (en) 2010-08-20 2013-03-28 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
EP3556396B1 (en) 2010-08-31 2022-04-20 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
SG10201912092VA (en) 2010-09-09 2020-02-27 Pfizer 4-1bb binding molecules
EP2614085B1 (en) 2010-09-10 2016-04-20 Apexigen, Inc. Anti-il-1 beta antibodies and methods of use
GB201016864D0 (en) 2010-10-06 2010-11-17 Univ Aston Therapeutic methods
ES2660895T3 (es) 2010-10-29 2018-03-26 Ablynx N.V. Método para la producción de dominios variables individuales de inmunoglobulina
CA2822366A1 (en) 2010-12-23 2012-06-28 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
US9598499B2 (en) 2010-12-30 2017-03-21 Institut National De La Santé Et De La Recherche Médicale (Inserm) Antigen binding formats for use in therapeutic treatments or diagnostic assays
EP3763740A1 (en) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
US9447187B2 (en) 2011-02-03 2016-09-20 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
JP6097702B2 (ja) 2011-03-03 2017-03-15 アペクシジェン, インコーポレイテッド 抗il−6受容体抗体およびその使用方法
JP5832559B2 (ja) 2011-03-10 2015-12-16 オメロス コーポレーション exvivoにおける加速された抗体進化による抗FN14モノクローナル抗体の生成
WO2012124567A1 (ja) * 2011-03-11 2012-09-20 株式会社カネカ Vps遺伝子が破壊されている酵母を用いる異種タンパク質の製造方法
TWI719112B (zh) 2011-03-16 2021-02-21 賽諾菲公司 雙重v區類抗體蛋白質之用途
US9468679B2 (en) 2011-03-28 2016-10-18 Ablynx N.V. Method for producing solid formulations comprising immunoglobulin single variable domains
MX341076B (es) 2011-03-31 2016-08-04 Merck Sharp & Dohme Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
US9534039B2 (en) 2011-05-09 2017-01-03 Ablynx N.V. Method for the production of immunoglobulin single variable domains
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
CN116948019A (zh) 2011-05-17 2023-10-27 洛克菲勒大学 人类免疫缺陷病毒中和抗体及其使用方法
KR102072250B1 (ko) 2011-05-27 2020-03-02 아블린쓰 엔.브이. Rankl 결합 펩티드를 이용한 골 재흡수 억제
US9580480B2 (en) 2011-05-31 2017-02-28 Massachusetts Institute Of Technology Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
JP2014525736A (ja) 2011-06-23 2014-10-02 アブリンクス エン.ヴェー. IgEに対する免疫グロブリン単一可変ドメイン
CN103649121B (zh) 2011-06-28 2016-10-19 牛津生物疗法有限公司 针对adp-核糖基环化酶2的抗体
PL2726094T3 (pl) 2011-06-28 2017-06-30 Oxford Biotherapeutics Ltd Cel terapeutyczny i diagnostyczny
PT2717917T (pt) 2011-07-05 2016-07-27 Bioasis Technologies Inc Conjugados de anticorpos p97
AU2012294673B2 (en) 2011-08-05 2015-11-26 Bioasis Technologies Inc. p97 fragments with transfer activity
CA2844289C (en) 2011-08-12 2020-01-14 Omeros Corporation Anti-fzd10 monoclonal antibodies and methods for their use
WO2013033069A1 (en) 2011-08-30 2013-03-07 Theraclone Sciences, Inc. Human rhinovirus (hrv) antibodies
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
US20140235492A1 (en) 2011-09-20 2014-08-21 Institut National De La Sante Et De La Recherche Medicate (Inserm) Methods for preparing single domain antibody microarrays
EP2747782B1 (en) 2011-09-23 2018-01-17 Ablynx NV Prolonged inhibition of interleukin-6 mediated signaling
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
US9575073B2 (en) 2011-10-10 2017-02-21 Rutgers, The State University Of New Jersey Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
KR102027603B1 (ko) 2011-11-02 2019-10-01 아펙시젠, 인코포레이티드 항-kdr 항체 및 사용 방법
KR20140091031A (ko) 2011-11-04 2014-07-18 노파르티스 아게 저밀도 지단백질-관련 단백질 6 (lrp6) - 반감기 연장제 구축물
KR102083957B1 (ko) 2011-12-05 2020-03-04 노파르티스 아게 표피 성장 인자 수용체 3 (her3)에 대한 항체
JP2015500829A (ja) 2011-12-05 2015-01-08 ノバルティス アーゲー 上皮細胞増殖因子受容体3(her3)のドメインiiに対するher3の抗体
CN104080480A (zh) 2012-01-01 2014-10-01 奇比艾企业有限公司 用于选择性递送治疗剂和诊断剂的endo180靶向微粒
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
DK2804878T3 (en) 2012-01-20 2018-12-17 Genzyme Corp ANTI-CXCR3 ANTIBODIES
US20150301068A1 (en) 2012-01-30 2015-10-22 Vib Vzw Means and method for diagnosis and treatment of alzheimer's disease
WO2013121042A1 (en) 2012-02-16 2013-08-22 Vib Vzw PP2A SUBUNITS IN DNA REPAIR, THE PP2A B55α SUBUNIT AS NOVEL PHD2 INTERACTING PROTEIN, AND IMPLICATIONS FOR CANCER
JP6262196B2 (ja) 2012-03-15 2018-01-17 オメロス コーポレーション 標的配列の多様化のための組成物および方法
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
DK2838918T3 (da) 2012-04-20 2019-08-12 Merus Nv Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
AU2013265665B2 (en) 2012-05-24 2017-10-26 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US11339208B1 (en) 2012-05-31 2022-05-24 United States Of America As Represented By The Secretary Of The Air Force Camelidae single-domain antibodies against Yersinia pestis and methods of use
EP2687595B1 (en) * 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
CN104812775B (zh) 2012-07-25 2019-05-03 塞尔德克斯医疗公司 抗kit抗体及其用途
US9932565B2 (en) 2012-07-31 2018-04-03 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
US9549993B2 (en) 2012-10-02 2017-01-24 Rutgers, The State University Of New Jersey Specific delivery of toxins conjugated with antibodies to activate matripase
EA035012B1 (ru) 2012-10-18 2020-04-17 Рокфеллер Юниверсити (Дзе) Нейтрализующие анти-вич-антитела широкого спектра действия
CN104918957B (zh) 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
JP2016509582A (ja) 2012-12-19 2016-03-31 アンプリミューン, インコーポレイテッド 抗ヒトb7−h4抗体およびその使用
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
BR112015014621A2 (pt) 2012-12-21 2017-10-03 Amplimmune Inc Anticorpos anti-h7cr
CN112858672A (zh) 2013-01-30 2021-05-28 弗拉芒区生物技术研究所 用于筛选和药物发现目的的新型嵌合多肽
PL2953973T3 (pl) 2013-02-05 2020-01-31 Vib Vzw Środki wiążące muskarynowy receptor acetylocholiny i ich zastosowania
US9963513B2 (en) 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
HK1218576A1 (zh) 2013-02-28 2017-02-24 Caprion Proteomics Inc. 结核病生物标志物及其用途
EP2970433B1 (en) 2013-03-13 2019-09-18 Bioasis Technologies Inc. Fragments of p97 and uses thereof
JP2016514130A (ja) 2013-03-14 2016-05-19 ノバルティス アーゲー Notch3に対する抗体
CA2907397C (en) 2013-03-15 2022-11-22 Anthrogenesis Corporation Modified t lymphocytes
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
AU2014229020B2 (en) 2013-03-15 2017-09-28 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
WO2014140376A1 (en) 2013-03-15 2014-09-18 Vib Vzw Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases
MD20180107A2 (ro) 2013-03-18 2019-06-30 Biocerox Products B.V. Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora
US10233249B2 (en) 2013-03-19 2019-03-19 Beijing Shenogen Pharma Group Ltd. Antibodies and methods for treating estrogen receptor-associated diseases
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
JP6967347B2 (ja) 2013-04-29 2021-11-17 バイオタリス・エン・フェー スフィンゴ脂質に結合する抗体を含む農薬組成物
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
MX376808B (es) 2013-05-24 2025-03-07 Medimmune Llc Anticuerpos anti-b7-h5 y sus usos.
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
SG10201708143QA (en) 2013-06-06 2017-11-29 Pf Medicament Anti-c10orf54 antibodies and uses thereof
KR101809072B1 (ko) 2013-08-02 2017-12-14 화이자 인코포레이티드 항-cxcr4 항체 및 항체-약물 접합체
SI3011345T1 (sl) 2013-08-07 2017-12-29 Alexion Pharmaceuticals, Inc. Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
EP3038657A2 (en) 2013-08-28 2016-07-06 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
EP4124624A3 (en) 2013-12-20 2023-05-03 Intervet International B.V. Antibodies against canine pd-1
CA2936728C (en) 2014-01-30 2023-06-20 Vib Vzw Opioid receptor binding agents and uses thereof
JP6603227B2 (ja) 2014-02-03 2019-11-06 バイオアシス テクノロジーズ インコーポレイテッド P97融合タンパク質
EP3102245B1 (en) 2014-02-05 2021-09-08 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
ES2762672T3 (es) 2014-02-19 2020-05-25 Bioasis Technologies Inc Proteínas de fusión de P97-IDS
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
CN106255410B (zh) 2014-03-21 2020-01-10 瑞泽恩制药公司 产生单结构域结合蛋白的非人动物
EP3738597A1 (en) 2014-04-25 2020-11-18 Bluebird Bio, Inc. Improved methods for manufacturing adoptive cell therapies
IL296691B2 (en) 2014-04-25 2023-11-01 2Seventy Bio Inc MND promoter chimeric antigen receptors
WO2015168521A2 (en) 2014-05-01 2015-11-05 Bioasis Technologies, Inc. P97-polynucleotide conjugates
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
DK3148579T3 (da) 2014-05-28 2021-03-08 Agenus Inc Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
LT3149172T (lt) 2014-05-29 2018-09-10 Quark Pharmaceuticals, Inc. Būdai ir kompozicijos, skirti organų išeminės reperfuzijos pažeidimo prevencijai
CN106793780B (zh) 2014-06-06 2020-05-26 蓝鸟生物公司 改善的t细胞组合物
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
WO2016012363A1 (en) 2014-07-22 2016-01-28 Vib Vzw Methods to select for agents that stabilize protein complexes
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
JP6289733B2 (ja) 2014-07-29 2018-03-07 フレイエ ユニヴェルシテイト ブリュッセルVrije Universiteit Brussel 癌の予防及び/又は治療に用いるための放射標識抗体断片
US20180036442A1 (en) 2014-07-29 2018-02-08 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
CR20170060A (es) 2014-08-19 2017-04-18 Merck Sharp & Dohme Anticuerpos anti tigit
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
BR112017006552A2 (pt) 2014-10-03 2017-12-19 Ntercept Llc composições e métodos para inibir a atividade biológica de biomoléculas solúveis
CA2963692A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
AR102550A1 (es) 2014-11-05 2017-03-08 Agrosavfe Nv Planta transgénica que comprende un polinucleótido que codifica un dominio variable de anticuerpo de cadena pesada
WO2016094837A2 (en) 2014-12-11 2016-06-16 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
EP3971210A1 (en) 2014-12-12 2022-03-23 2seventy bio, Inc. Composition for use in the treatment of b cell related conditions in a subject in need thereof comprisine an effector cell comrising a bcma chimeric antigen receptors
CN107406497A (zh) 2014-12-19 2017-11-28 埃博灵克斯股份有限公司 半胱氨酸连接的纳米抗体二聚体
EP3789039A1 (en) 2014-12-22 2021-03-10 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
WO2016109415A1 (en) 2014-12-30 2016-07-07 Celgene Corporation Anti-cd47 antibodies and uses thereof
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
KR102740384B1 (ko) 2015-03-03 2024-12-06 키맵 리미티드 항체, 용도 및 방법
CA2979976A1 (en) 2015-03-17 2016-09-22 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
WO2016151558A1 (en) 2015-03-25 2016-09-29 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of factor d of the alternative complement pathway
ES2721781T3 (es) 2015-03-25 2019-08-05 Alexion Pharma Inc Un método para medir la actividad proteasa de C3 y C5 convertasa de la vía de complemento alternativa
MX2017012662A (es) 2015-03-31 2018-05-11 Vhsquared Ltd Polipeptidos.
KR102789821B1 (ko) 2015-03-31 2025-04-02 소리소 파마슈티컬스 인크. 프로테아제-절단가능 링커를 갖는 펩티드 구조물
JP2018511346A (ja) 2015-03-31 2018-04-26 ブイエイチスクエアード リミテッド ポリペプチド
JP6938383B2 (ja) 2015-04-02 2021-09-22 インターベット インターナショナル ベー. フェー. イヌインターロイキン4受容体アルファに対する抗体
ES2841437T3 (es) 2015-04-13 2021-07-08 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de enfermedades hemorrágicas
AU2016256911B2 (en) 2015-05-07 2022-03-31 Agenus Inc. Anti-OX40 antibodies and methods of use thereof
EP3294334B1 (en) 2015-05-11 2020-07-08 The Johns Hopkins University Autoimmune antibodies for use in inhibiting cancer cell growth
CA2986765A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
EP3307777A4 (en) 2015-06-11 2019-02-13 Wuxi Biologics (Shanghai) Co. Ltd. NOVEL ANTI-PD-L1 ANTIBODIES
JP6432942B2 (ja) * 2015-06-23 2018-12-05 日立オートモティブシステムズ株式会社 ブレーキ装置
WO2017013026A1 (en) 2015-07-17 2017-01-26 Vrije Universiteit Brussel Radiolabelled antibody fragments for use in treating cancer
AU2016302881B2 (en) 2015-08-03 2022-09-15 Bristol-Myers Squibb Company Monoclonal antibodies against BCMA
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
MX392711B (es) 2015-08-11 2025-03-24 Wuxi Biologics Ireland Ltd Anticuerpos anti-pd-1 novedosos.
CN105063082A (zh) * 2015-09-07 2015-11-18 复旦大学 用于在马克思克鲁维酵母营养缺陷型菌株中进行外源基因分泌表达的重组载体
CN105132452A (zh) * 2015-09-07 2015-12-09 复旦大学 在马克斯克鲁维酵母营养缺陷型菌株中表达融合了组氨酸标签的外源基因的重组载体
ES2911015T3 (es) 2015-08-31 2022-05-17 Helixmith Co Ltd Receptores quiméricos de antígeno anti-sialil Tn
EP3344656A1 (en) 2015-09-01 2018-07-11 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
PH12018500645B1 (en) 2015-09-24 2022-10-21 Abvitro Llc Hiv antibody compositions and methods of use
EP3359566A1 (en) 2015-10-07 2018-08-15 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
WO2017062835A2 (en) 2015-10-09 2017-04-13 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
CN108473561B (zh) 2015-11-27 2022-12-16 埃博灵克斯股份有限公司 抑制cd40l的多肽
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
JP7000322B2 (ja) 2015-12-16 2022-02-04 メルク・シャープ・アンド・ドーム・コーポレーション 抗lag3抗体および抗原結合性フラグメント
CA3005696A1 (en) 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド (エイチケイ) リミテッド 多重特異性Fab融合タンパクおよびその使用
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
EP3433615A1 (en) 2016-03-21 2019-01-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for diagnosis and treatment of solar lentigo
CA3007135A1 (en) 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Novel anti-pd-l1 antibodies
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
EP3433275A1 (en) 2016-03-24 2019-01-30 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
WO2017176762A1 (en) 2016-04-06 2017-10-12 Nanotics, Llc Particles comprising subparticles or nucleic acid scaffolds
WO2017180993A1 (en) 2016-04-14 2017-10-19 Bluebird Bio, Inc. Salvage chimeric antigen receptor systems
CA3019588A1 (en) 2016-04-20 2017-10-26 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
WO2017182605A1 (en) 2016-04-22 2017-10-26 Université Libre de Bruxelles A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
US11243214B2 (en) 2016-04-22 2022-02-08 Université Libre de Bruxelles Biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
CA3022697A1 (en) 2016-05-02 2017-11-09 Ablynx Nv Treatment of rsv infection
MX389710B (es) 2016-05-27 2025-03-20 Agenus Inc Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
EP3481864A1 (en) 2016-07-08 2019-05-15 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US20200148750A1 (en) 2016-07-21 2020-05-14 Emory University Ebola Virus Antibodies and Binding Agents Derived Therefrom
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
WO2018026969A2 (en) 2016-08-03 2018-02-08 Achaogen, Inc. Plazomicin antibodies and methods of use
WO2018027039A1 (en) 2016-08-03 2018-02-08 Nextcure, Inc. Compositions and methods for modulating lair signal transduction
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
KR20190049866A (ko) 2016-09-20 2019-05-09 우시 바이올로직스 아일랜드 리미티드 신규한 항-pcsk9 항체
DK3515478T3 (da) 2016-09-21 2024-05-21 Nextcure Inc Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
EP4360714A3 (en) 2016-09-21 2024-07-24 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
KR102576042B1 (ko) 2016-10-11 2023-09-07 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
JP7256741B2 (ja) 2016-10-12 2023-04-12 アレクシオン ファーマシューティカルズ, インコーポレイテッド 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗c5抗体の有効性
EP3529618B1 (en) 2016-10-19 2020-12-02 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5 in a sample
ES2888904T3 (es) 2016-10-19 2022-01-10 Alexion Pharma Inc Un método de cuantificación de C5a sin unir en una muestra
WO2018081400A1 (en) 2016-10-27 2018-05-03 Alexion Pharmaceuticals Inc. Assay for c5b-9 deposition in complement-associated disorders
CN110352073A (zh) 2016-10-28 2019-10-18 机敏医药股份有限公司 针对timp-2的抗体用于改善肾功能的用途
WO2018078083A1 (en) 2016-10-28 2018-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating multiple myeloma
EP3535295A1 (en) 2016-11-02 2019-09-11 EngMab Sàrl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR20240005168A (ko) 2016-11-04 2024-01-11 2세븐티 바이오, 인코포레이티드 항-bcma car t 세포 조성물
KR102431830B1 (ko) 2016-11-07 2022-08-16 주식회사 뉴라클사이언스 서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
IL317416A (en) 2016-11-16 2025-02-01 Ablynx Nv T cell-recruiting polypeptides capable of binding CD123 and TCR alpha/beta
DK3541833T5 (da) 2016-11-17 2024-09-02 2Seventy Bio Inc TGFß signalkonverter
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
US10759855B2 (en) 2016-12-02 2020-09-01 Rigel Pharmaceuticals, Inc. Antigen binding molecules to TIGIT
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
FI3551660T3 (fi) 2016-12-07 2023-12-11 Agenus Inc Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
ES2988845T3 (es) 2017-01-09 2024-11-21 Onkosxcel Therapeutics Llc Procedimientos predictivos y diagnósticos para cáncer de próstata
WO2018141753A1 (en) 2017-01-31 2018-08-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating squamous cell carcinomas
BR112019017853A2 (pt) 2017-02-28 2021-04-27 Vib Vzw Meios e métodos para liberação oral de proteína
CN110831961B (zh) 2017-03-03 2024-01-02 黑曜石疗法公司 用于免疫疗法的cd19组合物和方法
CN110913954A (zh) 2017-03-03 2020-03-24 黑曜石疗法公司 免疫疗法的组合物和方法
CN110753702B (zh) 2017-03-15 2022-09-20 清华大学 抗trkb抗体
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
KR20190133198A (ko) 2017-03-27 2019-12-02 셀진 코포레이션 면역원성의 감소를 위한 방법 및 조성물
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗cd137抗体およびその使用方法
EP3610264A1 (en) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2018189403A1 (en) 2017-04-14 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancer
EP3612648A1 (en) 2017-04-18 2020-02-26 Université Libre de Bruxelles Biomarkers and targets for proliferative diseases
WO2018195034A1 (en) 2017-04-19 2018-10-25 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
CN110536694A (zh) 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
SG11201909395TA (en) 2017-04-27 2019-11-28 Tesaro Inc Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
RS64576B1 (sr) 2017-05-01 2023-10-31 Agenus Inc Anti-tigit antitela i postupci njihove primene
CA3062238A1 (en) 2017-05-11 2018-11-15 Vib Vzw Glycosylation of variable immunoglobulin domains
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2018208553A1 (en) 2017-05-12 2018-11-15 Augusta University Research Institute, Inc. Human alpha fetoprotein-specific t cell receptors and uses thereof
CN110997001A (zh) 2017-06-02 2020-04-10 默克专利股份有限公司 Mmp13结合免疫球蛋白
MX2019014504A (es) 2017-06-02 2020-07-20 Merck Patent Gmbh Inmunoglobulinas de union a agrecano.
CN111032695B (zh) 2017-06-02 2024-06-25 默克专利股份有限公司 结合adamts的免疫球蛋白
MX2019014397A (es) 2017-06-02 2020-02-10 Merck Patent Gmbh Polipeptidos que enlazan adamts5, mmp13 y agrecano.
EP3415010A1 (en) 2017-06-13 2018-12-19 Agrosavfe Nv Insect-controlling polypeptides and methods
JP7076059B2 (ja) 2017-06-27 2022-05-27 ニューラクル サイエンス カンパニー リミテッド 抗fam19a5抗体及びその用途
CA3068672A1 (en) 2017-06-28 2019-01-03 The Rockefeller University Anti-mertk agonistic antibody-drug conjugates and uses thereof
EP3652209A2 (en) 2017-07-11 2020-05-20 Compass Therapeutics LLC Agonist antibodies that bind human cd137 and uses thereof
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
CA3070253A1 (en) 2017-07-19 2019-01-24 Vib Vzw Serum albumin binding agents
US11485781B2 (en) 2017-08-17 2022-11-01 Massachusetts Institute Of Technology Multiple specificity binders of CXC chemokines
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
CN118909118A (zh) 2017-09-07 2024-11-08 奥古斯塔大学研究所公司 程序性细胞死亡蛋白1抗体
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
CA3080103A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
EP4635987A3 (en) 2017-10-31 2026-01-14 Vib Vzw Novel antigen-binding chimeric proteins and methods and uses thereof
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019106126A1 (en) 2017-12-01 2019-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Mdm2 modulators for the diagnosis and treatment of liposarcoma
JP2021505208A (ja) 2017-12-05 2021-02-18 セリアド エス.アー.Celyad S.A. 養子細胞療法用細胞の持続性を向上するための組成物および方法
US11639496B2 (en) 2017-12-05 2023-05-02 Celyad S.A. Reducing fratricide of immune cells expressing NKG2D-based receptors
US11946094B2 (en) 2017-12-10 2024-04-02 Augusta University Research Institute, Inc. Combination therapies and methods of use thereof
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
JP7418332B2 (ja) 2017-12-19 2024-01-19 スロゼン オペレーティング, インコーポレイテッド 抗フリズルド抗体及び使用方法
JP7317016B2 (ja) 2017-12-19 2023-07-28 スロゼン オペレーティング, インコーポレイテッド 抗lrp5/6抗体及び使用方法
PE20201339A1 (es) 2017-12-19 2020-11-25 Univ Rockefeller Variantes de dominio de fc de igg humana con funcion efectora mejorada
WO2019121872A1 (en) 2017-12-20 2019-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of liver cancer
CN108218990B (zh) 2017-12-29 2021-03-02 南京优迈生物科技有限公司 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US10899823B2 (en) 2018-01-18 2021-01-26 California Institute Of Technology Programmable protein circuits in living cells
US11965191B2 (en) 2018-01-18 2024-04-23 California Institute Of Technology Programmable protein circuits in living cells
WO2019147670A1 (en) 2018-01-23 2019-08-01 Nextcure, Inc. B7-h4 antibodies and methods of use thereof
EP3746123A4 (en) 2018-02-01 2021-12-01 Memorial Sloan-Kettering Cancer Center ANTIBODIES DIRECTED AGAINST GALECTIN-3 AND THEIR METHODS OF USE
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
US11802303B2 (en) 2018-02-07 2023-10-31 Georgia Tech Research Corporation Methods for multiplexed cell isolation using DNA gates
WO2019155041A1 (en) 2018-02-12 2019-08-15 Vib Vzw Gβγ COMPLEX ANTIBODIES AND USES THEREOF
WO2019169229A1 (en) 2018-03-01 2019-09-06 Nextcure, Inc. Klrg1 binding compositions and methods of use thereof
EP3758742A1 (en) 2018-03-01 2021-01-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US10738128B2 (en) 2018-03-14 2020-08-11 Surface Oncology, Inc. Antibodies that bind CD39 and uses thereof
US11661452B2 (en) 2018-03-20 2023-05-30 WuXi Biologics Ireland Limited Anti-lag-3 antibody polypeptide
EP3768725A4 (en) 2018-03-20 2021-06-02 Wuxi Biologics Ireland Limited NEW ANTI-TIM-3 ANTIBODIES
EP3768317A4 (en) 2018-03-22 2021-12-22 Surface Oncology, Inc. ANTI-IL-27 ANTIBODIES AND USES THEREOF
JP7390729B2 (ja) 2018-03-23 2023-12-04 ユニヴェルシテ リブル ドゥ ブリュッセル Wntシグナル伝達アゴニスト分子
MX2020010091A (es) 2018-03-27 2021-01-15 Umc Utrecht Holding Bv Trombolisis direccionada para tratamiento de trombosis microvascular.
WO2019185683A1 (en) 2018-03-28 2019-10-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
US11505610B2 (en) 2018-04-06 2022-11-22 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
WO2019197683A1 (en) 2018-04-13 2019-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
US12048745B2 (en) 2018-05-01 2024-07-30 Augusta University Research Institute, Inc. Methods for detecting and reversing immune therapy resistance
WO2019211370A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2019211369A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
US20190345261A1 (en) 2018-05-10 2019-11-14 Sensei Biotherapeutics, Inc. Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
KR20240056644A (ko) 2018-05-10 2024-04-30 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
WO2019234099A1 (en) 2018-06-06 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
DK3806903T5 (da) 2018-06-14 2024-08-19 2Seventy Bio Inc Cd79a kimæriske antigenreceptorer
CN119930818A (zh) 2018-06-29 2025-05-06 爱必泰生物有限公司 抗l1cam抗体及其用途
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP3820906B1 (en) 2018-07-05 2025-10-15 Surrozen Operating, Inc. Multi-specific wnt surrogate molecules and uses thereof
CN112689516A (zh) 2018-07-11 2021-04-20 细胞基因公司 抗bcma嵌合抗原受体的用途
WO2020016160A1 (en) 2018-07-16 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat neurological diseases
WO2020016377A1 (en) 2018-07-19 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination for treating cancer
IL280199B2 (en) 2018-07-20 2025-08-01 Pf Medicament Receptor for vista
US20220162336A1 (en) 2018-07-22 2022-05-26 Bioasis Technologies, Inc. Treatment of lymphatic metastases
WO2020028909A1 (en) 2018-08-03 2020-02-06 Brown University Oral formulations with increased uptake
WO2020033926A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
US20210388089A1 (en) 2018-08-09 2021-12-16 Compass Therapeutics Llc Antigen binding agents that bind cd277 and uses thereof
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
US11453893B2 (en) 2018-08-30 2022-09-27 California Institute Of Technology RNA-based delivery systems with levels of control
EP3844180A4 (en) 2018-08-31 2022-07-20 California Institute of Technology Synthetic protein circuits detecting signal transducer activity
EP3848397A4 (en) 2018-09-04 2022-07-20 Nanjing Umab-Biopharma Co., Ltd. Fusion protein and its application in preparing medicine for treating tumor and/or viral infection
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
CN121021680A (zh) 2018-09-14 2025-11-28 洛克菲勒大学 抗hiv抗体10-1074变体
AU2019346335B2 (en) 2018-09-28 2024-07-25 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
AU2019352017A1 (en) 2018-10-03 2021-05-06 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
US12195539B2 (en) 2018-10-25 2025-01-14 Jjp Biologics Sp. Z O.O. Anti-human CD89 antibodies and uses thereof
EP3873455A1 (en) 2018-10-31 2021-09-08 Institut National de la Santé et de la Recherche Médicale (INSERM) Method for treating t-helper type 2 mediated disease
US12016885B2 (en) 2018-11-06 2024-06-25 Alsatech, Inc. Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab
WO2020102387A1 (en) 2018-11-13 2020-05-22 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
US12422441B2 (en) 2018-12-07 2025-09-23 Georgia Tech Research Corporation Antibodies that bind to natively folded myocilin
SG11202105161YA (en) 2018-12-13 2021-06-29 Surface Oncology Inc Anti-il-27 antibodies and uses thereof
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
CN113195533B (zh) 2019-01-02 2024-04-26 纽洛可科学有限公司 抗序列相似家族19成员a5的抗体及其使用方法
US11667676B2 (en) 2019-01-10 2023-06-06 California Institute Of Technology Synthetic system for tunable thresholding of protein signals
JP7539897B2 (ja) 2019-01-16 2024-08-26 コンパス セラピューティクス リミテッド ライアビリティ カンパニー ヒトcd137に結合する抗体の製剤およびその使用
JP2022522265A (ja) 2019-01-16 2022-04-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル エリスロフェロンの変異体及びその使用
US11254736B2 (en) 2019-02-15 2022-02-22 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
MA54955A (fr) 2019-02-15 2021-12-22 Integral Molecular Inc Anticorps anti-claudine 6 et leurs utilisations
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
ES2978570T3 (es) 2019-02-26 2024-09-16 Inspirna Inc Anticuerpos anti-MERTK de alta afinidad y sus usos
US11673953B2 (en) 2019-03-01 2023-06-13 Allogene Therapeutics, Inc. DLL3 targeting chimeric antigen receptors and binding agents
KR20210149251A (ko) 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
WO2020193740A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
US20220169706A1 (en) 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
WO2020205827A1 (en) 2019-04-01 2020-10-08 Rush University Medical Center Reagents and assays using modified integrin domains
WO2020208082A1 (en) 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cmv related diseases
CN114041057A (zh) 2019-04-29 2022-02-11 康福治疗有限公司 嵌合蛋白和筛选与gpcr结合的化合物和配体的方法
US20220289837A1 (en) 2019-04-30 2022-09-15 Vib Vzw Cystic Fibrosis Transmembrane Conductance Regulator Stabilizing Agents
KR20220045930A (ko) 2019-04-30 2022-04-13 마이얼로이드 테라퓨틱스, 인크. 조작된 키메라 융합 단백질 조성물 및 이의 사용 방법
AU2020275406A1 (en) 2019-05-13 2021-11-18 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
EP3969569A1 (en) 2019-05-14 2022-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
WO2020229648A1 (en) 2019-05-16 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat type 2 inflammation or mast-cell dependent disease
EP3976650A1 (en) 2019-05-28 2022-04-06 Vib Vzw Cancer treatment by targeting plexins in the immune compartment
WO2020239934A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
US20220235142A1 (en) 2019-06-04 2022-07-28 Shanghai GenBase Biotechnology Co., Ltd. Anti-ceacam5 monoclonal antibody, preparation method thereof and use thereof
EP3986570A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Compositions
CN114514243B (zh) 2019-06-21 2025-01-24 索瑞索制药公司 多肽
EP3986571A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
US11642409B2 (en) 2019-06-26 2023-05-09 Massachusetts Insttute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2021001539A1 (en) 2019-07-04 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy to detect and treat eosinophilic fasciitis
CA3145345A1 (en) 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies against canine ctla-4
KR20220053007A (ko) 2019-08-30 2022-04-28 아게누스 인코포레이티드 항-cd96 항체 및 이의 사용 방법
US20220340975A1 (en) 2019-09-05 2022-10-27 INSERM (Institute National de la Santé et de la Recherche Médicale) Method of treatment and pronostic of acute myeloid leukemia
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
TW202124444A (zh) 2019-09-16 2021-07-01 美商表面腫瘤學公司 抗cd39抗體組合物及方法
TWI875823B (zh) 2019-09-25 2025-03-11 美商表面腫瘤學有限責任公司 抗il-27抗體及用途
EP4034151A1 (en) 2019-09-27 2022-08-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of müllerian inhibiting substance inhibitors for treating cancer
TW202126295A (zh) 2019-09-27 2021-07-16 大陸商江蘇挪貝肽醫藥科技有限公司 一種治療心境障礙的方法
EP4048703A1 (en) 2019-10-21 2022-08-31 Vib Vzw Nanodisc-specific antigen-binding chimeric proteins
US11459389B2 (en) 2019-10-24 2022-10-04 Massachusetts Institute Of Technology Monoclonal antibodies that bind human CD161
WO2021086953A1 (en) 2019-10-28 2021-05-06 Georgia Tech Research Corporation Compositions and methods for prophylaxis of hiv
WO2021086948A1 (en) 2019-10-28 2021-05-06 Georgia Tech Research Corporation Mrna-encoded antibodies for contraception
CA3160178A1 (en) 2019-11-05 2021-05-14 Celgene Corporation Uses of anti-bcma chimeric antigen receptors
IL292879B2 (en) 2019-11-11 2025-08-01 Ibi Ag Innovative Bio Insecticides Ltd Nanoantibodies for insect control and their uses
WO2021105391A1 (en) 2019-11-27 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination comprising nupr1 inhibitors to treat cancer
WO2021105384A1 (en) 2019-11-27 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Targeting the nls region of nupr1 protein to treat cancer
EP4065603A1 (en) 2019-11-27 2022-10-05 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
EP4077372A1 (en) 2019-12-20 2022-10-26 Vib Vzw Nanobody exchange chromatography
AU2020407124A1 (en) 2019-12-20 2022-07-21 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1
KR20220128363A (ko) 2019-12-24 2022-09-20 제이제이피 바이오로직스 에스피. 제트 오.오. 항-인간 hvem(tnfrsf14) 항체 및 그의 용도
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
TWI906906B (zh) 2020-01-06 2025-12-01 美商法西尼克斯股份有限公司 抗ccr8抗體及其用途
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
AU2021225817A1 (en) 2020-02-24 2022-10-20 Immatics US, Inc. Methods for expanding T cells for the treatment of cancer and related malignancies
JP7814714B2 (ja) 2020-02-25 2026-02-17 ブイアイビー ブイゼットダブリュ ロイシンリッチリピートキナーゼ2のアロステリック調節因子
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
CA3173527A1 (en) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Methods for generating engineered memory-like nk cells and compositions thereof
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
BR112022018088A2 (pt) 2020-03-12 2023-01-17 Immune Onc Therapeutics Inc Novos anticorpos anti-lilrb4 e produtos derivados
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
CA3175873A1 (en) 2020-03-30 2021-10-07 Ablynx Nv Method for the production and purification of multivalent immunoglobulin single variable domains
EP4125379B1 (en) 2020-03-31 2024-08-21 Biotalys NV Anti-fungal polypeptides
CN113461817B (zh) 2020-03-31 2025-04-18 苏州泽璟生物制药股份有限公司 一种抗人cd47抗体及其抗原结合片段、制备方法和应用
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
JP2023522208A (ja) 2020-04-16 2023-05-29 アシスタンス ピュブリック-オピト ド パリ ウイルスによって引き起こされる補体媒介性障害を処置する方法
KR20230004739A (ko) 2020-04-21 2023-01-06 제이제이피 바이오로직스 에스피. 제트 오.오. 인간화 항-인간 cd89 항체 및 이의 용도
CN113527488B (zh) 2020-04-22 2026-04-17 迈威(上海)生物科技股份有限公司 一种靶向人程序性死亡配体1(pd-l1)的单可变域抗体及其衍生物
IL297412A (en) 2020-05-04 2022-12-01 Immunorizon Ltd Precursor tri-specific antibody constructs and methods of use thereof
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
EP4153192B8 (en) 2020-05-19 2024-09-04 Institut Curie Antagonist of cd44/hyaluronic acid pathway for use in a method for the treatment of cytokine release syndrome
US11820824B2 (en) 2020-06-02 2023-11-21 Arcus Biosciences, Inc. Antibodies to TIGIT
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
US20230218608A1 (en) 2020-06-18 2023-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
WO2022023583A1 (en) 2020-07-31 2022-02-03 Biotalys NV Expression host
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
WO2022060806A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
WO2022063947A1 (en) 2020-09-24 2022-03-31 Vib Vzw Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
WO2022063984A1 (en) 2020-09-25 2022-03-31 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
TW202228775A (zh) 2020-10-14 2022-08-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物及方法
WO2022084399A1 (en) 2020-10-21 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) C-terminal sparc fragments for treating cancer
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス,インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法
JP2023550309A (ja) 2020-11-04 2023-12-01 セルジーン コーポレーション 以前に抗がんアルキル化剤療法を受けた患者におけるcar t細胞療法
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
EP4272002A1 (en) 2020-12-04 2023-11-08 Celgene Corporation Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
JP7842101B2 (ja) 2020-12-18 2026-04-07 アブリンクス エン.ヴェー. IL-6およびTNF-αを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
EP4267617A1 (en) 2020-12-24 2023-11-01 Vib Vzw Human ccr8 binders
EP4267621A1 (en) 2020-12-24 2023-11-01 Vib Vzw Murine cross-reactive human ccr8 binders
US20240052044A1 (en) 2020-12-24 2024-02-15 Vib Vzw Non-blocking human ccr8 binders
JP2024504875A (ja) 2021-02-01 2024-02-01 ▲い▼尊生物医薬(浙江)有限公司 標的タンパク質分解システムおよびその応用
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
CA3207548A1 (en) 2021-02-05 2022-08-11 Xavier Saelens Sarbecovirus binders
US20240229154A9 (en) 2021-02-12 2024-07-11 Institut National de la Santé et de la Recherche Médicale Method for prognosis and treating a patient suffering from cancer
EP4294407A1 (en) 2021-02-17 2023-12-27 Vib Vzw Inhibition of slc4a4 in the treatment of cancer
IL305318A (en) 2021-02-19 2023-10-01 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
KR20240013094A (ko) 2021-03-17 2024-01-30 마이얼로이드 테라퓨틱스, 인크. 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법
WO2022199804A1 (en) 2021-03-24 2022-09-29 Vib Vzw Nek6 inhibition to treat als and ftd
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
JP2024515591A (ja) 2021-04-08 2024-04-10 マレンゴ・セラピューティクス,インコーポレーテッド Tcrに結合する多機能性分子およびその使用
EP4322937A1 (en) 2021-04-14 2024-02-21 Institut National de la Santé et de la Recherche Médicale (INSERM) New method to improve the anti-tumoral activity of macrophages
US20240228659A1 (en) 2021-04-14 2024-07-11 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve nk cells cytotoxicity
AU2022257093A1 (en) 2021-04-16 2023-11-02 Celgene Corporation T cell therapy in patients who have had prior stem cell transplant
MX2023013149A (es) 2021-05-07 2023-11-28 Surface Oncology Llc Anticuerpos anti-il-27 y usos de estos.
BR112023023642A2 (pt) 2021-05-11 2024-01-30 Myeloid Therapeutics Inc Métodos e composições para integração genômica
US20240261446A1 (en) 2021-05-17 2024-08-08 Université de Liège Anti-cd38 single domain antibodies in disease monitoring and treatment
EP4340879A4 (en) 2021-05-20 2025-03-26 Dianthus Therapeutics OpCo, Inc. Antibodies that bind to c1s and uses thereof
WO2022253910A1 (en) 2021-06-02 2022-12-08 INSERM (Institut National de la Santé et de la Recherche Médicale) A new method to treat an inflammatory skin disease
EP4357365A4 (en) 2021-06-16 2025-06-04 Shanghai Sinobay Biotechnology Co., Ltd. Antibodies against AXL protein and antigen-binding fragment thereof, as well as methods of production and use thereof
WO2022268993A1 (en) 2021-06-23 2022-12-29 Vib Vzw Means and methods for selection of specific binders
US20240343811A1 (en) 2021-06-29 2024-10-17 Shandong Simcere Biopharmacutical Co., Ltd. Cd16 antibody and use thereof
WO2023016828A2 (en) 2021-07-30 2023-02-16 Vib Vzw Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
EP4378954A4 (en) 2021-07-30 2025-05-21 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-pvrig/anti-tigit bispecific antibody and application
CN118019548A (zh) 2021-08-06 2024-05-10 蒙彼利埃癌症研究所 用于治疗癌症的方法
TW202320850A (zh) 2021-08-10 2023-06-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物、劑量及方法
WO2023034809A1 (en) 2021-08-30 2023-03-09 Lassen Therapeutics 1, Inc. Anti-il-11rα antibodies
WO2023041744A1 (en) 2021-09-17 2023-03-23 Institut Curie Bet inhibitors for treating pab1 deficient cancer
EP4405680A1 (en) 2021-09-20 2024-07-31 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
EP4413165A1 (en) 2021-10-06 2024-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
WO2023057601A1 (en) 2021-10-06 2023-04-13 Biotalys NV Anti-fungal polypeptides
CA3234995A1 (en) 2021-10-14 2023-04-20 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
WO2023073099A1 (en) 2021-10-28 2023-05-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
WO2023078906A1 (en) 2021-11-03 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating acute myeloid leukemia
EP4180518A1 (en) 2021-11-12 2023-05-17 Istituto Europeo di Oncologia S.r.l. T cells and uses thereof
US20250019708A1 (en) 2021-11-19 2025-01-16 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
WO2023089159A1 (en) 2021-11-22 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy targeting stroma/tumor cell crosstalk to treat a cancer
WO2023099763A1 (en) 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer
CN118696058A (zh) 2021-12-03 2024-09-24 山东先声生物制药有限公司 抗bcma纳米抗体及其应用
JP2024546914A (ja) 2021-12-15 2024-12-26 インテリウス・バイオセラピューティクス・インコーポレイテッド 偽型ウイルス粒子、それを含む組成物、及びそれらの使用
AU2022409733A1 (en) 2021-12-17 2024-08-01 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123
US20250145705A1 (en) 2021-12-31 2025-05-08 Shandong Simcere Biopharmaceutical Co., Ltd. Gprc5d antibody and application thereof
CA3248241A1 (en) 2022-01-12 2023-07-20 Vib Vzw HUMAN NTCP BINDERS FOR THERAPEUTIC USE AND TARGETED LIVER ADMINISTRATION
JP2025504020A (ja) 2022-01-28 2025-02-06 ジョージアミューン・インコーポレイテッド Pd-1アゴニストであるプログラム細胞死タンパク質1に対する抗体
EP4473108A1 (en) 2022-02-02 2024-12-11 Biotalys NV Methods for genome editing
EP4476250A1 (en) 2022-02-07 2024-12-18 Vib Vzw Engineered stabilizing aglycosylated fc-regions
WO2023151894A1 (en) 2022-02-11 2023-08-17 Henkel Ag & Co. Kgaa Process for the synthesis of alpha-methylene-gamma-butyrolactone
US20250144042A1 (en) 2022-02-22 2025-05-08 Brown University Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
US20250230261A1 (en) 2022-03-23 2025-07-17 Bodhi Bio Llc Compositions and methods for antigen-specific therapy
US20250235534A1 (en) 2022-04-13 2025-07-24 Vib Vzw An LTBR Agonist In Combination Therapy Against Cancer
WO2023215719A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
EP4519324A1 (en) 2022-05-02 2025-03-12 UMC Utrecht Holding B.V. Single domain antibodies for the detection of plasmin-cleaved vwf
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same
TWI866210B (zh) 2022-05-17 2024-12-11 大陸商蘇州創勝醫藥集團有限公司 雙功能蛋白質及其製劑和用途
EP4526340A1 (en) 2022-05-18 2025-03-26 Vib Vzw Sarbecovirus spike s2 subunit binders
US20230372395A1 (en) 2022-05-19 2023-11-23 Massachusetts Institute Of Technology Car cells targeting an inserted ligand
WO2023230116A1 (en) 2022-05-25 2023-11-30 Surface Oncology, Inc. Use of anti-il-27 antibodies
US20240026001A1 (en) 2022-05-25 2024-01-25 Surface Oncology, Inc. Use of anti-il-27 antibodies
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
KR20250021313A (ko) 2022-06-06 2025-02-12 산둥심시어 바이오파마슈티칼 씨오., 엘티디. Bcma, gprc5d 및 t 세포를 표적으로 하는 다중특이적 항체 및 그 응용
AU2023285085A1 (en) 2022-06-07 2024-12-19 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
JP2025523630A (ja) 2022-07-04 2025-07-23 ブイアイビー ブイゼットダブリュ 血液-脳脊髄液関門通過抗体
WO2024017915A1 (en) 2022-07-18 2024-01-25 Ablynx N.V. Cx3cr1-binding compounds, uses thereof and related methods
CA3262768A1 (en) 2022-07-25 2024-02-01 Interius Biotherapeutics, Inc. Mutated polypeptides, compositions containing them, and their uses
WO2024028476A1 (en) 2022-08-05 2024-02-08 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of th2-mediated diseases
WO2024037910A1 (en) 2022-08-17 2024-02-22 Institut National de la Santé et de la Recherche Médicale Syk inhibitors for use in the treatment of cancer
CN120129696A (zh) 2022-09-01 2025-06-10 乔治亚大学研究基金公司 用于指导载脂蛋白l1诱导哺乳动物细胞死亡的组合物和方法
CN120035450A (zh) 2022-09-06 2025-05-23 阿雷克森制药公司 造血干细胞移植物相关血栓性微血管病(hsct-tma)患者的诊断和预后生物标志物谱
CA3266599A1 (en) 2022-09-07 2024-11-07 Quantitative Biosciences, Inc. UNIQUE VARIABLE DOMAIN ANTIBODIES SPECIFIC TO FENTANYL AND USE IN A CONTINUOUS AGGLUTINATION TEST
EP4594348A1 (en) 2022-09-27 2025-08-06 Vib Vzw Antivirals against human parainfluenza virus
WO2024105091A1 (en) 2022-11-15 2024-05-23 Imec Vzw Method and system for droplet manipulation
AU2023385709A1 (en) 2022-11-21 2025-06-12 Dianthus Therapeutics Opco, Inc. Antibodies that bind to c1s and uses thereof
TW202440623A (zh) 2022-11-28 2024-10-16 美商艾洛基因醫療公司 靶向密連蛋白18﹒2之嵌合抗原受體及結合劑以及其用途
EP4626933A1 (en) 2022-11-30 2025-10-08 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
US20240200085A1 (en) 2022-12-15 2024-06-20 Aarhus Universitet Synthetic activation of multimeric transmembrane receptors
WO2024133937A1 (en) 2022-12-22 2024-06-27 Biotalys NV Methods for genome editing
WO2024133723A1 (en) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
CN120476149A (zh) 2022-12-23 2025-08-12 成都恩沐生物科技有限公司 靶向gprc5d的多特异性多肽复合物
EP4643878A2 (en) 2022-12-29 2025-11-05 Suzhou Transcenta Therapeutics Co., Ltd. Pharmaceutical preparation comprising therapeutic antibody and use thereof
US20260026500A1 (en) 2022-12-29 2026-01-29 Biotalys NV Agrochemical compositions
EP4642233A1 (en) 2022-12-30 2025-11-05 Biotalys NV Agglomerate
EP4642916A2 (en) 2022-12-30 2025-11-05 Biotalys NV Secretion signals
WO2024141638A1 (en) 2022-12-30 2024-07-04 Biotalys NV Self-emulsifiable concentrate
TW202430560A (zh) 2023-01-06 2024-08-01 美商拉森醫療公司 抗il-18bp抗體
CN120787238A (zh) 2023-01-06 2025-10-14 拉森医疗公司 用于治疗甲状腺眼病的抗IL-11Rα抗体
JP2026503273A (ja) 2023-01-06 2026-01-28 ラッセン・セラピューティクス・インコーポレイテッド 抗il-18bp抗体
EP4655323A1 (en) 2023-01-27 2025-12-03 Vrije Universiteit Brussel Cd8b-binding polypeptides
WO2024156888A1 (en) 2023-01-27 2024-08-02 Vib Vzw Cd163-binding conjugates
WO2024165710A1 (en) 2023-02-09 2024-08-15 Seni-Preps B.V. Immunoglobulin single variable domains that inhibit urease and use thereof
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
WO2024184812A1 (en) 2023-03-06 2024-09-12 Beigene Switzerland Gmbh Anti-cldn6 antibodies and methods of use
WO2024184811A1 (en) 2023-03-06 2024-09-12 Beigene Switzerland Gmbh Anti-cd3 multispecific antibodies and methods of use
AR132063A1 (es) 2023-03-06 2025-05-21 Beigene Switzerland Gmbh Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso
JP2026509422A (ja) 2023-03-07 2026-03-19 アンスティテュ キュリィ Brca関連癌におけるung/udgの阻害
EP4676453A1 (en) 2023-03-08 2026-01-14 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of food allergy
AU2024236537A1 (en) 2023-03-14 2025-09-04 Aarhus Universitet Genetically altered nfr5 receptor kinases
WO2024194401A1 (en) 2023-03-21 2024-09-26 Institut Curie Vps4b inhibitor for use in methods for the treatment of hrd cancer
WO2024194673A1 (en) 2023-03-21 2024-09-26 Institut Curie Methods for the treatment of dedifferentiated liposarcoma
WO2024194402A1 (en) 2023-03-21 2024-09-26 Institut Curie Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
AU2024240821A1 (en) 2023-03-23 2025-11-06 Bodhi Bio Llc Compositions and methods for antigen-specific therapy
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies
WO2024213782A1 (en) 2023-04-13 2024-10-17 Institut Curie Methods for the treatment of t-cell acute lymphoblastic leukemia
WO2024226829A2 (en) 2023-04-26 2024-10-31 Yale University Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
CN121511260A (zh) 2023-05-11 2026-02-10 非营利性组织佛兰芒综合大学生物技术研究所 SLC4A4/NBCe1抑制剂
AU2024276787A1 (en) 2023-05-23 2026-01-15 Allygen Group Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
WO2024256527A1 (en) 2023-06-13 2024-12-19 Institut National de la Santé et de la Recherche Médicale Use of a cxcl 10 inhibitor for the treatment of transplant vasculopathy
WO2024259305A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Vhh polypeptides that bind to mesothelin, compositions and methods of use thereof
WO2024259299A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Compositions and methods for identification of vhh antibodies that bind a target antigen
WO2024261344A1 (en) 2023-06-23 2024-12-26 Vib Vzw Novel binders targeting the multi-drug resistant pathogen acinetobacter baumannii
EP4483951A1 (en) 2023-06-30 2025-01-01 Université de Liège Single-domain antibody for inhibition of neutrophil elastase activity
TW202509078A (zh) 2023-07-07 2025-03-01 美商維里迪恩醫療股份有限公司 治療慢性甲狀腺眼病之方法
WO2025032112A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of type 2-mediated diseases
WO2025068393A1 (en) 2023-09-27 2025-04-03 Institut Curie Methods for the treatment of fibrotic related diseases
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025078851A1 (en) 2023-10-11 2025-04-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods of treating cognitive deficit
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants
WO2025093683A1 (en) 2023-11-03 2025-05-08 Neuvasq Biotechnologies Sa Wnt7 signaling agonists
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
WO2025125577A1 (en) 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
WO2025136985A1 (en) 2023-12-17 2025-06-26 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
US12378306B2 (en) 2023-12-22 2025-08-05 Biotalys NV Anti-fungal VHH antibodies
WO2025151502A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Modified antibodies
WO2025151492A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151496A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025154058A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect hsp70 nanobodies and uses thereof
WO2025154056A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect cda nanobodies and uses thereof
WO2025162980A1 (en) 2024-01-30 2025-08-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of breast cancer using a jnk-1 inhibitor
WO2025168716A1 (en) 2024-02-07 2025-08-14 Eyebiotech Limited Compositions, doses, and methods for treatment of ocular diseases
WO2025176777A1 (en) 2024-02-20 2025-08-28 Institut Curie Dut inhibition in homologous recombination deficiency cancer
WO2025179282A1 (en) 2024-02-23 2025-08-28 Flatiron Bio, Llc Antibodies targeting epstein-barr virus proteins and methods of use
WO2025181155A1 (en) 2024-02-26 2025-09-04 Vib Vzw Human beta-glucocerebrosidase binders and uses thereof
WO2025184211A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
US20250361320A1 (en) 2024-02-27 2025-11-27 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025191018A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Mrgpre binding agent for use in the treatment of inflammatory and pain disorders
WO2025196308A1 (en) 2024-03-22 2025-09-25 Vib Vzw Means and methods for displaying fc-containing proteins on cells and selection thereof
WO2025212726A2 (en) 2024-04-04 2025-10-09 Compass Therapeutics, Inc. Combination of antibodies targeting dll4/vegf and cd137 agonists or anti-pd1/anti-pd-l1 antibodies for the treatment of cancer
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025224050A1 (en) 2024-04-22 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of patients suffering from hypomelanosis of ito
WO2025226603A1 (en) 2024-04-22 2025-10-30 Surface Oncology, LLC Methods for treating cancer using anti-ccr8 antibodies
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
WO2025238157A1 (en) 2024-05-15 2025-11-20 Katholieke Universiteit Leuven Multispecific binding agent suitable for use in cancer immune therapy
WO2025245381A1 (en) 2024-05-23 2025-11-27 The Trustrees Of Dartmouth College Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
WO2026002934A1 (en) 2024-06-25 2026-01-02 Institut National de la Santé et de la Recherche Médicale Combination of a slc16a1 inhibitor and a smad3 inhibitor for treating cancer
WO2026003239A2 (en) 2024-06-28 2026-01-02 Institut National de la Santé et de la Recherche Médicale Method to improve macrophages functions
WO2026008665A1 (en) 2024-07-01 2026-01-08 Vib Vzw Binders of the pd-1•pd-l1 complex and their use
WO2026011013A1 (en) 2024-07-02 2026-01-08 Epibiologics, Inc. Binding agents and uses thereof
WO2026008785A1 (en) 2024-07-03 2026-01-08 Biotalys NV Agrochemical compositions
WO2026013153A1 (en) 2024-07-10 2026-01-15 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from myc-high tumors
WO2026027659A1 (en) 2024-07-31 2026-02-05 Seni-Preps B.V. Improved immunoglobulin single variable domains that inhibit urease and use thereof
WO2026037841A1 (en) 2024-08-12 2026-02-19 ONA Therapeutics S.L. Anti-fgfr4 molecules and uses thereof
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2026053130A1 (en) 2024-09-03 2026-03-12 Mirobio Limited Anti-btla antibodies and uses of the same
WO2026055167A1 (en) 2024-09-05 2026-03-12 Surface Oncology, LLC Anti-il-27 antibodies and use of biomarkers in uses thereof
WO2026055168A1 (en) 2024-09-06 2026-03-12 Surface Oncology, LLC Anti-il-27 antibodies and uses and doses thereof
WO2026052851A2 (en) 2024-09-09 2026-03-12 Institut National de la Santé et de la Recherche Médicale Inhibitor of ciliogenesis for use in a method of preventing therapeutic resistance in cancer
WO2026060159A1 (en) 2024-09-13 2026-03-19 Gilead Sciences, Inc. Vhhs against hsv and uses of the same
WO2026068859A1 (en) 2024-09-30 2026-04-02 Université Libre de Bruxelles Wnt signaling agonist molecules in the treatment of a bone-related disease or disorder
WO2026076388A1 (en) 2024-10-03 2026-04-09 The Broad Institute, Inc. Vhh polypeptides that bind to claudin-18, compositions and methods of use thereof
WO2026087355A1 (en) 2024-10-22 2026-04-30 Biotalys NV Downstream processing
US20260115307A1 (en) 2024-10-31 2026-04-30 Bristol-Myers Squibb Company Anti-fucosyl-gm1 antibody drug conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL82935A0 (en) 1986-08-12 1987-12-20 Phillips Petroleum Co Secretion of heterologous proteins from yeast
CA1341411C (en) 1988-04-16 2002-12-17 Lutz Riechmann Method for producing fv fragments in eukaryotic cells
GB8927230D0 (en) 1989-12-01 1990-01-31 Unilever Plc Reagents
FI913434A7 (fi) 1990-07-16 1992-01-17 Technical Research Centre F Finland Rekombinanta fusionsproteiner vilka utsoendras.
PT1621554E (pt) * 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
EP0584421A1 (en) 1992-08-21 1994-03-02 Cécile Casterman Immunoglobulins devoid of light chains
US6005079A (en) * 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
PL178685B1 (pl) * 1992-08-28 2000-06-30 Zymogenetics Inc Cząsteczka DNA kodująca receptor glukagonu lub peptyd receptora glukagonu, konstrukty DNA, komórka gospodarza zawierająca konstrukty DNA, peptyd receptora glukagonu i sposoby wytwarzania receptora glukagonu lub peptydu receptora glukagonu

Also Published As

Publication number Publication date
DK0698097T3 (da) 2001-10-08
DE69427974T2 (de) 2001-12-06
WO1994025591A1 (en) 1994-11-10
US6838254B1 (en) 2005-01-04
AU6796094A (en) 1994-11-21
ATE204325T1 (de) 2001-09-15
US20050130266A1 (en) 2005-06-16
US7794981B2 (en) 2010-09-14
DE69427974D1 (de) 2001-09-20

Similar Documents

Publication Publication Date Title
DK0698097T3 (da) Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
DK1107989T3 (da) Ekspression og eksport af angiostatin og endostatin som immunfusiner
DE69737683D1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
ES2161751T3 (es) Anticuerpo monoclonal que se une especificamente al endotelio vascular tumoral y usos del mismo.
CO5050255A1 (es) Anticuerpo especifico de fap con productividad mejorada
FI911275A0 (fi) Cd25-bindande molekyler.
MX2022007035A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp.
PE20090046A1 (es) Anticuerpo recombinante humanizado anti-interleuquina 10
CY1118709T1 (el) Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf
DK0554344T3 (da) Farmaceutisk præparat til behandling eller forebyggelse af en malign tumor
AR021296A1 (es) Un anticuerpo humanizado especifico para 4-1bb humano y composiciones farmaceuticas que lo comprenden
WO2004065416A3 (en) Synthetic antibody phage libraries
ATE230020T1 (de) Katalytische antikörperkomponente
ATE200679T1 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
ATE388162T1 (de) Verfahren zur beseitigung von viren
ATE166882T1 (de) Monoklonale antikörper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
DE59309458D1 (de) Synthetische Peptide, Antikörper dagegen und ihre Verwendung
PE20232050A1 (es) Anticuerpos anti-cd19 y estructuras car-t
PT856520E (pt) Metodo de preparacao de um anticorpo monoclonal, anticorpo monoclonal, uma composicao farmaceutica e um reagente de diagnostico
BR0015287A (pt) Moléculas recombinantes de fusão
DE69934250D1 (de) Zusammensetzungen und verfahren zur herstellung monoklonaler antikörper, repräsentativ für einen spezifischen zelltyp
MX2022009138A (es) Anticuerpos y fragmentos de anticuerpos anti-her2 condicionalmente activos, sus inmunoconjugados y usos de estos.
ATE141415T1 (de) Konjugate von antikörpern mit variablen domänen
WO2024011177A3 (en) Dll3 antigen binding constructs
PT1097210E (pt) Reagente imunologico que interage especificamente com o dominio extracelular da cadeia zeta humana

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 698097

Country of ref document: ES